Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CETP | P11597 | 3/20 | 0.33 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7608836 | 0.77 | PTGS1 (0.37) | TSHRLMNAPTGS1HPGD | |
| SCHEMBL7650534 | 0.76 | ELANE (0.40) | LMNAGAAHTTCETP | |
| SCHEMBL7607748 | 0.73 | AKR1B1 (0.42) | AKR1B1RPS6KB2DAOMMP12TSHR | |
| SCHEMBL7609331 | 0.73 | AKR1B1 (0.39) | AKR1B1TSHRHPGDCETPLTB4R | |
| SCHEMBL7606732 | 0.72 | GABRP (0.46) | AKR1B1TSHRABCC4LMNAGAA | |
| SCHEMBL16563827 | 0.70 | GAA (0.45) | AKR1B1RPS6KB2TSHRLMNAGAA | |
| SCHEMBL3836998 | 0.69 | SRC (0.57) | TSHRHTTHPGDCYP2C19 | |
| Phenylacetic Acid SCHEMBL27735060 | 0.68 | AKR1B1 (0.81) | AKR1B1TSHRABCC4LMNAGAA | |
| Phenylacetic Acid SCHEMBL28260960 | 0.68 | AKR1B1 (0.81) | AKR1B1TSHRABCC4LMNAGAA | |
| SCHEMBL7609475 | 0.68 | KDM4E (0.50) | GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2002515040-A | — | — | 2002-05-21 | — | — | JP | claimed |
| EP-0954295-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-10 | — | — | EP | claimed |
| WO-1997048409-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | claimed |
| EP-0954295-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-10 | — | — | EP | disclosed |
| WO-1997048409-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | disclosed |